TY - JOUR
T1 - Venous Thromboembolism
T2 - A Survey of Oral Anticoagulant Preferences in the Treatment of Challenging Patient Populations
AU - Moyer, Genevieve Claire
AU - Bannow, Bethany Samuelson
AU - Thornburg, Courtney
AU - Rosovsky, Rachel
AU - Wang, Tzu Fei
AU - Woller, Scott
AU - Thornhill, Dianne
AU - Kreuziger, Lisa Baumann
N1 - Funding Information:
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Scott Wol-ler, MD, received investigator-initiated grant funding from Bristol-Myers-Squibb. Statistical support for this study was provided by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) under grant number 2H30MC24049, Mountain States Hemophilia Network.
Publisher Copyright:
© The Author(s) 2018.
PY - 2018/12/1
Y1 - 2018/12/1
N2 - Venous thromboembolism (VTE) is a highly morbid condition with several available oral anticoagulant treatment options. Numerous studies have been published comparing warfarin to direct oral anticoagulants; however, several populations remain underrepresented in these reports. We surveyed members of The Venous ThromboEmbolism Network U.S. working group regarding their oral anticoagulant preferences for the treatment of VTE in different and challenging populations. In individuals with VTE and no other medical comorbidities, respondents preferred either rivaroxaban (48.7%) or apixaban (48.7%). Apixaban (53.3%) was preferred in elderly individuals with an increased risk of bleeding. Warfarin was preferred in individuals with liver or kidney dysfunction (42% and 47%), altered metabolism (>55%), and antiphospholipid antibody syndrome (84.2%). Low-molecular-weight heparin was preferred in individuals with malignancy (56.6%), followed by edoxaban (23.7%). These findings may help guide clinicians when choosing an anticoagulant in these challenging situations and demonstrate the urgent need for additional study in these groups.
AB - Venous thromboembolism (VTE) is a highly morbid condition with several available oral anticoagulant treatment options. Numerous studies have been published comparing warfarin to direct oral anticoagulants; however, several populations remain underrepresented in these reports. We surveyed members of The Venous ThromboEmbolism Network U.S. working group regarding their oral anticoagulant preferences for the treatment of VTE in different and challenging populations. In individuals with VTE and no other medical comorbidities, respondents preferred either rivaroxaban (48.7%) or apixaban (48.7%). Apixaban (53.3%) was preferred in elderly individuals with an increased risk of bleeding. Warfarin was preferred in individuals with liver or kidney dysfunction (42% and 47%), altered metabolism (>55%), and antiphospholipid antibody syndrome (84.2%). Low-molecular-weight heparin was preferred in individuals with malignancy (56.6%), followed by edoxaban (23.7%). These findings may help guide clinicians when choosing an anticoagulant in these challenging situations and demonstrate the urgent need for additional study in these groups.
KW - anticoagulants
KW - deep vein thrombosis
KW - factor Xa inhibitors
KW - low-molecular-weight heparins
KW - lupus inhibitor
KW - venous thromboembolism
UR - http://www.scopus.com/inward/record.url?scp=85059087361&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059087361&partnerID=8YFLogxK
U2 - 10.1177/1076029618804080
DO - 10.1177/1076029618804080
M3 - Article
C2 - 30278776
AN - SCOPUS:85059087361
SN - 1076-0296
VL - 24
SP - 209S-216S
JO - Clinical and Applied Thrombosis/Hemostasis
JF - Clinical and Applied Thrombosis/Hemostasis
IS - 9_suppl
ER -